Abstract
In the last five years, everolimus has demonstrated efficacy in the treatment of neuroendocrine tumors (NETs) of different origins; its efficacy and safety were explored in the RADIANT trials, the last of which (RADIANT-4) has been recently published (December 2015). Overall, evidence collected from the RADIANT studies holds promise to change clinical practice for the treatment of NETs.In this paper, we comment on the role of everolimus within the therapeutic algorithm for NETs treatment, based on the systematic analysis of the RADIANT trials and our experience.
Highlights
The incidence of neuroendocrine tumors (NETs) is increasing worldwide [1]
We provide our personal view on how do the results of the RADIANT studies impact on the management of NET patients, and we comment on the role of everolimus within the therapeutic algorithm for NETs treatment on the basis of the systematic analysis of the RADIANT trials and our experience
Given the favorable results obtained in the pivotal studies, everolimus has been approved for the treatment of advanced pancreatic NET (pNET) and its approval procedure in GI and lung carcinoids is ongoing
Summary
The incidence of neuroendocrine tumors (NETs) is increasing worldwide [1]. NETs represent a heterogeneous class of neoplasms, with tumor behavior - and patient survival - depending upon several factors including primary site, tumor histology, proliferative index, and staging [2]. Double-blind, placebo controlled phase III RADIANT 2 trial, the combination of everolimus (10 mg/day) plus octreotide LAR was compared with octreotide LAR alone in 429 patients with low-grade or intermediate-grade NET associated with carcinoid syndrome [11].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
